Cover Image
市場調查報告書

糖尿病足部潰傷 : 開發平台分析

Diabetic Foot Ulcers - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192554
出版日期 內容資訊 英文 157 Pages
訂單完成後即時交付
價格
Back to Top
糖尿病足部潰傷 : 開發平台分析 Diabetic Foot Ulcers - Pipeline Review, H2 2016
出版日期: 2016年11月23日 內容資訊: 英文 157 Pages
簡介

所謂糖尿病足部潰瘍,是第一型、第二型糖尿病患者的足部產生潰爛的部分。主要症狀是足部、下肢潰爛、潰瘍、水泡,及步行困難、腳部變色(黑、青、紅)、足部體溫降低或發熱、皮膚紅腫、其他感染疾病的徵兆等。易罹病素質有糖尿病神經病變和末稍血管疾病、足部變形、抽煙相關的病史等。

本報告提供全球各國治療糖尿病足部潰傷所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

糖尿病足部潰傷概要

治療藥的開發

  • 糖尿病足部潰傷開發中產品:概要
  • 糖尿病足部潰傷開發中產品:比較分析

各企業開發中的糖尿病足部潰傷治療藥

大學/研究機關研究中的糖尿病足部潰傷治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

糖尿病足部潰傷治療藥:開發中的產品一覽(各企業)

糖尿病足部潰傷治療藥:研究中的產品一覽(各大學/研究機關)

糖尿病足部潰傷治療藥的開發企業

  • Adocia
  • Bayer AG
  • CardioVascular BioTherapeutics, Inc.
  • Celgene Corporation
  • CytoTools AG
  • Dipexium Pharmaceuticals LLC
  • EyeGene, Inc.
  • FirstString Research, Inc.
  • GlaxoSmithKline Plc
  • Human Stem Cells Institute
  • Innovaxis
  • Izun Pharmaceuticals Corporation
  • Karyopharm Therapeutics, Inc.
  • Lytix Biopharma AS
  • MediWound Ltd.
  • NovaLead Pharma Pvt. Ltd.
  • Oneness Biotech Co., Ltd.
  • Osiris Therapeutics, Inc.
  • Pherecydes Pharma SA
  • Plurogen Therapeutics, Inc.
  • Sanofi
  • Stratatech Corporation
  • TechnoPhage SA
  • TGV-Laboratories
  • Theravasc, Inc.
  • Tissue Therapies Limited
  • USV Limited
  • Vida Therapeutics Inc.
  • ViroMed Co., Ltd.

糖尿病足部潰傷:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

糖尿病足部潰傷治療藥:開發中產品的最新趨勢

糖尿病足部潰傷治療藥:暫停開發的產品

糖尿病足部潰傷治療藥:中止開發的產品

糖尿病足部潰傷相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8696IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Pipeline Review, H2 2016, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 16, 5, 16, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Diabetic Foot Ulcers.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Diabetic Foot Ulcers Overview
  • Therapeutics Development
  • Pipeline Products for Diabetic Foot Ulcers - Overview
  • Pipeline Products for Diabetic Foot Ulcers - Comparative Analysis
  • Diabetic Foot Ulcers - Therapeutics under Development by Companies
  • Diabetic Foot Ulcers - Therapeutics under Investigation by Universities/Institutes
  • Diabetic Foot Ulcers - Pipeline Products Glance
  • Late Stage Products
  • Clinical Stage Products
  • Early Stage Products
  • Unknown Stage Products
  • Diabetic Foot Ulcers - Products under Development by Companies
  • Diabetic Foot Ulcers - Products under Investigation by Universities/Institutes
  • Diabetic Foot Ulcers - Companies Involved in Therapeutics Development
  • ANP Technologies Inc
  • CardioVascular BioTherapeutics Inc
  • Celgene Corp
  • Chrysalis BioTherapeutics Inc
  • CytoTools AG
  • EyeGene Inc
  • FirstString Research Inc
  • Genentech Inc
  • GlaxoSmithKline Plc
  • Human Stem Cells Institute
  • Izun Pharmaceuticals Corp
  • Karyopharm Therapeutics Inc
  • Lakewood-Amedex Inc
  • Lytix Biopharma AS
  • Mallinckrodt Plc
  • MediWound Ltd
  • NovaLead Pharma Pvt Ltd
  • Oneness Biotech Co Ltd
  • Osiris Therapeutics Inc
  • Pherecydes Pharma SA
  • Plurogen Therapeutics Inc
  • TechnoPhage SA
  • TGV-Laboratories
  • Theravasc Inc
  • Topadur Pharma AG
  • USV Pvt Ltd
  • viDA Therapeutics Inc
  • ViroMed Co Ltd
  • Diabetic Foot Ulcers - Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Drug Profiles
  • 3K3A-APC - Drug Profile
  • ALLO-ASC - Drug Profile
  • ANP-017 - Drug Profile
  • AP-102 - Drug Profile
  • APO-2 - Drug Profile
  • becaplermin biosimilar - Drug Profile
  • Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile
  • Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile
  • CL-05 - Drug Profile
  • CODA-001 - Drug Profile
  • CVBT-141B - Drug Profile
  • Cyndacel-M - Drug Profile
  • daprodustat - Drug Profile
  • EG-Decorin - Drug Profile
  • epidermal growth factor biosimilar - Drug Profile
  • EscharEx - Drug Profile
  • esmolol hydrochloride - Drug Profile
  • Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile
  • Granexin - Drug Profile
  • Heberprot-P - Drug Profile
  • IMSP-001 - Drug Profile
  • IZN-6D4 - Drug Profile
  • LTX-109 - Drug Profile
  • MT-003 - Drug Profile
  • Mul-1867 - Drug Profile
  • Neovasculgen - Drug Profile
  • Nu-2 - Drug Profile
  • Nu-3 - Drug Profile
  • ON-101 - Drug Profile
  • OTI-1501 - Drug Profile
  • PDA-002 - Drug Profile
  • PluroGel N - Drug Profile
  • PP-2351 - Drug Profile
  • Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile
  • RG-7880 - Drug Profile
  • rusalatide acetate - Drug Profile
  • selinexor - Drug Profile
  • sodium nitrite SR - Drug Profile
  • Stathmin-1 - Drug Profile
  • TOPN-53 - Drug Profile
  • TP-102 - Drug Profile
  • V-10 - Drug Profile
  • VM-202 - Drug Profile
  • VTI-1000 Series - Drug Profile
  • VTI-3000 Series - Drug Profile
  • Diabetic Foot Ulcers - Dormant Projects
  • Diabetic Foot Ulcers - Discontinued Products
  • Diabetic Foot Ulcers - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Diabetic Foot Ulcers, H2 2016
  • Number of Products under Development for Diabetic Foot Ulcers - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Diabetic Foot Ulcers - Pipeline by ANP Technologies Inc, H2 2016
  • Diabetic Foot Ulcers - Pipeline by CardioVascular BioTherapeutics Inc, H2 2016
  • Diabetic Foot Ulcers - Pipeline by Celgene Corp, H2 2016
  • Diabetic Foot Ulcers - Pipeline by Chrysalis BioTherapeutics Inc, H2 2016
  • Diabetic Foot Ulcers - Pipeline by CytoTools AG, H2 2016
  • Diabetic Foot Ulcers - Pipeline by EyeGene Inc, H2 2016
  • Diabetic Foot Ulcers - Pipeline by FirstString Research Inc, H2 2016
  • Diabetic Foot Ulcers - Pipeline by Genentech Inc, H2 2016
  • Diabetic Foot Ulcers - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Diabetic Foot Ulcers - Pipeline by Human Stem Cells Institute, H2 2016
  • Diabetic Foot Ulcers - Pipeline by Izun Pharmaceuticals Corp, H2 2016
  • Diabetic Foot Ulcers - Pipeline by Karyopharm Therapeutics Inc, H2 2016
  • Diabetic Foot Ulcers - Pipeline by Lakewood-Amedex Inc, H2 2016
  • Diabetic Foot Ulcers - Pipeline by Lytix Biopharma AS, H2 2016
  • Diabetic Foot Ulcers - Pipeline by Mallinckrodt Plc, H2 2016
  • Diabetic Foot Ulcers - Pipeline by MediWound Ltd, H2 2016
  • Diabetic Foot Ulcers - Pipeline by NovaLead Pharma Pvt Ltd, H2 2016
  • Diabetic Foot Ulcers - Pipeline by Oneness Biotech Co Ltd, H2 2016
  • Diabetic Foot Ulcers - Pipeline by Osiris Therapeutics Inc, H2 2016
  • Diabetic Foot Ulcers - Pipeline by Pherecydes Pharma SA, H2 2016
  • Diabetic Foot Ulcers - Pipeline by Plurogen Therapeutics Inc, H2 2016
  • Diabetic Foot Ulcers - Pipeline by TechnoPhage SA, H2 2016
  • Diabetic Foot Ulcers - Pipeline by TGV-Laboratories, H2 2016
  • Diabetic Foot Ulcers - Pipeline by Theravasc Inc, H2 2016
  • Diabetic Foot Ulcers - Pipeline by Topadur Pharma AG, H2 2016
  • Diabetic Foot Ulcers - Pipeline by USV Pvt Ltd, H2 2016
  • Diabetic Foot Ulcers - Pipeline by viDA Therapeutics Inc, H2 2016
  • Diabetic Foot Ulcers - Pipeline by ViroMed Co Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Diabetic Foot Ulcers - Dormant Projects, H2 2016
  • Diabetic Foot Ulcers - Dormant Projects (Contd..1), H2 2016
  • Diabetic Foot Ulcers - Dormant Projects (Contd..2), H2 2016
  • Diabetic Foot Ulcers - Dormant Projects (Contd..3), H2 2016
  • Diabetic Foot Ulcers - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Diabetic Foot Ulcers, H2 2016
  • Number of Products under Development for Diabetic Foot Ulcers - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top